SKNO1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
AML · Acute Myeloid Leukemia
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- AML
- cancer_type_detailed
- Acute Myeloid Leukemia
- subtype
- —
- cancer_type
- AML
- ccle_sample_id
- SKNO1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
- synthetic_from_ccle
- true
- display_name
- SKNO-1
- ccle_lineage
- blood
- ccle_lineage_subtype
- AML
- oncotree_code
- AML
- cancer_type_detailed
- Acute Myeloid Leukemia
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+1.095
- MYC_TARGETS_V1+0.822
- E2F_TARGETS+0.697
- G2M_CHECKPOINT+0.599
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.403
- OXIDATIVE_PHOSPHORYLATION+0.379
- DNA_REPAIR+0.307
- MTORC1_SIGNALING+0.296
- PI3K_AKT_MTOR_SIGNALING+0.208
- ADIPOGENESIS+0.202
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.634
- NOTCH_SIGNALING-0.499
- TGF_BETA_SIGNALING-0.470
- TNFA_SIGNALING_VIA_NFKB-0.466
- COAGULATION-0.426
- APICAL_SURFACE-0.384
- HEDGEHOG_SIGNALING-0.381
- MYOGENESIS-0.373
- UV_RESPONSE_DN-0.369
- WNT_BETA_CATENIN_SIGNALING-0.356
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | NB4_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.949 |
| 2 | MOLM13_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.910 |
| 3 | SRR8518323 | — | E | 0.875 |
| 4 | U937_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.868 |
| 5 | 504282dd-4fef-4f70-a709-6a545d00a263 | — | — | 0.864 |
| 6 | TCGA-58-8387-01A-11R-2296-07 | — | cohortSQ2 | 0.862 |
| 7 | SIGM5_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.857 |
| 8 | TCGA-22-4613-01A-01R-1443-07 | — | cohortSQ2 | 0.855 |
| 9 | MV411_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.854 |
| 10 | 98e3beb5-bff2-4c4e-b492-c4ed7dda9d9c | — | — | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 1.095 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.822 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.697 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.599 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.403 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.379 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.307 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.296 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.208 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.202 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.162 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.152 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.138 | Inavolisib | — uncovered |
| PEROXISOME | 0.135 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.048 | Inavolisib | — uncovered |